Low frequency of filaggrin null mutations in Croatia and their relation with allergic diseases

I Sabolić Pipinić1, V M Varnai, R Turk

  • 1Occupational Health and Environmental Medicine Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia. ivanasp@imi.hr

Insights

Filaggrin gene (FLG) null mutations are uncommon in Croatia and do not predict common allergic diseases. However, FLG mutations are linked to skin symptoms, suggesting a latitude-dependent distribution in Europe.

Area of Science:

  • Genetics
  • Dermatology
  • Allergology

Background:

  • Filaggrin gene (FLG) null mutations are associated with atopic dermatitis.
  • Understanding the prevalence and impact of FLG mutations in diverse populations is crucial.

Purpose of the Study:

  • To determine the prevalence of specific FLG null mutations (R501X, 2282del4, R2447X, S3247X) in the Croatian population.
  • To investigate the role of these mutations in allergic diseases: atopic dermatitis, allergic rhinitis, asthma, and allergic contact dermatitis (ACD).

Main Methods:

  • Genotyping of FLG null mutations in 423 Croatian freshmen with diagnosed allergic diseases.
  • Analysis of allergic disease prevalence (symptoms and sensitization markers) in mutation carriers versus wild-type FLG subjects.

Main Results:

  • FLG null mutations were found in 2.6% of subjects (11/423), with R501X (0.2%) and 2282del4 (2.4%) being the only identified mutations.
  • No significant association was found between FLG null mutations and the occurrence of atopic dermatitis, allergic rhinitis, or asthma.
  • FLG null mutations were confirmed as an independent predictor of skin symptoms (OR 17.19, P < 0.001), independent of allergic sensitization.

Conclusions:

  • The frequency of FLG null mutations in Croatia is low, supporting a north-south gradient in Europe.
  • FLG null mutations are not predictive of major allergic diseases but are strongly associated with skin symptoms.

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Types of Intermediate Filaments01:31

Types of Intermediate Filaments

The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
Cytoskeletal Linker Proteins - Plakins01:09

Cytoskeletal Linker Proteins - Plakins

Plakins are large proteins with binding domains for microtubules, microfilaments, intermediate filaments, and membrane-associated protein complexes at cell junctions. Plakin functions are evolutionarily conserved and are primarily involved in organizing the different components of the cytoskeleton by crosslinking them to each other and connecting them to the cell-matrix and cell adhesion complexes. They are also known to interact with signal transducers, serve as scaffolds for signaling...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...